Abstract:Abstract Recent next-generation sequencing experiments have brought success in identifying cancer genes that were highly frequently mutated in tumors. As genomic sequencing experiments continue to identify large numbers of novel cancer mutations, one big challenge will be distinguishing driver mutations from passenger mutations. Driver mutations are the ones that have a role in oncogenesis or in the cancer phenotype, whereas passenger mutations are co-traveler that accumulate through DNA replication but are irrelevant to tumor development. From statistical point of view, driver genes are defined as those for which the non-silent mutation rate is significantly greater than a background (or passenger) mutation rate estimated from silent mutations. Statistical methods are now actively being developed to attempt to assess functional significance of a mutated gene in cancer sequencing studies. However, embedding biological knowledge on mutational process in tumors into statistical models is not trivial. These biological considerations include length of protein coding regions, gene structure, transcript isoforms, difference in mutation types, variation in background mutation rates, redundancy of the genetic code, multiple mutations in one gene, and functional consequence of different tumor types. They have not yet been fully addressed by current methods and tools for identifying driver genes. Driver mutations could be either common or rare among tumors. Identification of rare driver mutations may pose a potential challenge. In addition, mutation in one member of a collection of functionally related genes may result in the same net effect, and/or mutations in certain genes may be observed less frequently if they play functional roles in later stages of tumor development. At the pathway level, the frequency of rare driver mutations is accumulated in that pathway which warrants sufficient detection power. Thus, there is an increasing interest in the identification of driver pathways in tumor formation and progression. To meet these challenges, we developed a tool-DrGaP for identify driver genes and pathways in cancer sequencing studies. We introduced the Poisson processes to model the random nature of somatic mutation under no selection pressure. The new model can handle the identification of both driver genes and pathways or any gene sets in the same statistical framework. The new tool provides several significant improvements and increased power over current existing methods through simulations. To illustrate its utility, we applied the DrGaP to analysis of a recent lung cancer sequencing study. The DrGaP identified a few novel driver genes that were missed by previous methods, demonstrating its high accuracy and sensitivity. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3971. doi:1538-7445.AM2012-3971

Cancer Genome Landscapes

The Genomic Landscapes of Human Breast and Colorectal Cancers

Mutational landscape and significance across 12 major cancer types

Accelerating the understanding of cancer biology through the lens of genomics

Oncogenic Signaling Pathways in The Cancer Genome Atlas

Pan-cancer analysis of whole genomes

Abstract 3971: DrGaP: A Powerful Tool for Identifying Driver Genes and Pathways in Cancer Sequencing Studies

Analysis of 10,478 cancer genomes identifies candidate driver genes and opportunities for precision oncology

Global mapping of cancers: The Cancer Genome Atlas and beyond

The Immune Landscape of Cancer

The Cancer Genome Anatomy Project: EST sequencing and the genetics of cancer progression

The Cancer Genomics and Global Cancer Genome Collaboration

An expanded universe of cancer targets

Genomic Landscape of Gastric Cancer: Molecular Classification and Potential Targets

A Pan-Cancer Compendium of Genes Deregulated by Somatic Genomic Rearrangement Across More Than 1,400 Cases.

A Genome-Wide Comprehensive Analysis of Alterations in Driver Genes in Non-Small-cell Lung Cancer

On the discovered Cancer Driving Nucleotides (CDNs)-Distributions across genes, cancer types and patients

Neo-Darwinian Principles Exemplified in Cancer Genomics

Using Departments of Pathology And

A Pan‐cancer Atlas of Cancer Hallmark‐associated Candidate Driver Lncrnas

Deciphering oncogenic drivers: from single genes to integrated pathways.